Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

7 Customer Reviews

  • C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

    D, Scramble (SCR), H82, H865, and H1836 cells were treated with AZD1775 (100 nmol/L) and temozolomide (1 μmol/L) for 24 hours; WEE1 KD cells were treated with just temozolomide (1 μmol/L) for 24 hours. The cells were lysed at 24 hours and subjected to Western blot analysis for phosphorylated WEE1 (pWEE1_S642), pCDC2_Y15 (WEE1 downstream effector), γH2AX (DNA damage marker), PH3 (mitotic marker), cleaved caspase-3 (apoptotic marker), and actin (loading control). E, SCR and WEE1 KD H82, H865, and H1836 cells were treated as described in D and subjected to Western blot analysis for DNA repair markers pATM_S1981, MRE11, RAD51, and E2F1. Actin was used as a loading control.

    Clin Cancer Res, 2017, 23(20):6239-6253. Temozolomide purchased from Selleck.

  • Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

    J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

  • Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

    Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

  • Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfIbVU1QCCq NYWwb3VbUUN3ME2xN|kvOjEkgJpCtgKBkTVwOUWg{txO M{XRNlI2QTZyMkiy
KellyCis83 M2O5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu5OFghcA>? NWO0bFgxUUN3ME2yOVEvODEkgJpCtgKBkTF3Lke1JO69VQ>? M3fZRVI2QTZyMkiy
SK-N-AS NFPhN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLxWo1kPDhiaB?= Mn[0TWM2OD1{MkeuO|DjiIoEsfMAjVIzNjF3IN88US=> M4\SO|I2QTZyMkiy
SK-N-ASCis24 NHLKOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLHOFghcA>? NYTueJk3UUN3ME20PFAvPjEkgJpCtgKBkTFyMT6xOUDPxE1? NI\EPGYzPTl4MEK4Ni=>
CHP-212 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXK0PEBp NIHa[YxKSzVyPUeuPVfjiIoEsfMAjVAvPjlizszN NXXnfFlXOjV7NkCyPFI>
CHP-212Cis100 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWm0PEBp MYfJR|UxRTlwNUZihKnDueLCiUCuPFgh|ryP MV6yOVk3ODJ6Mh?=
U87  Mn;FSpVv[3Srb36gRZN{[Xl? NEPIfIYyODBizszN MnTkNlQuPzJiaB?= NXG3SJdmcW6mdXPld{BF[1JzIHX4dJJme3Orb36= NIjFUpYzPThyOEi2PC=>
LN229 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke4NE02OCEQvF2= MYXJR|UxRTF4IN88US=> MUCyOVc2ODJ5Mx?=
TR-LN229 NUT1d2o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\sSFAuPTBizszN Mnu5TWM2OD15NzFOwG0> MWKyOVc2ODJ5Mx?=
U87  M2PTTmFxd3C2b4Ppd{BCe3OjeR?= M{jISFDjiJN{MEFihKnDvU1? M3LKfVI1KGh? MW\lcohidmOnczDDVUBqdmS3Y3XkJIFxd3C2b4Ppdy=> NWjhOIhlOjV4OEG2Olg>
U251MG MorqRZBweHSxc3nzJGF{e2G7 NEH1UlkyODEEoN88US=> NESzO5Y1QCCq NWH2ZVU5WEKV NGXTc4pqdmS3Y3XzJIFxd3C2b4Ppdy=> MUGyOVY5ODR4NB?=
U87MG NYHEUmJGSXCxcITvd4l{KEG|c3H5 M1z3WFExOMLizszN MlK3OFghcA>? M1XzNXBDWw>? NF\sXJBqdmS3Y3XzJIFxd3C2b4Ppdy=> NFfSeVIzPTZ6MES2OC=>
U87 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS1NE0{PTBizszN MlX2OFjDqGkEoB?= M1HVUIlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 NETYNXIzPTV3NEKyNy=>
U118  MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X4blUxNTN3MDFOwG0> MY[0POKhcMLi MYHpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> NVPDZodbOjV3NUSyNlM>
U87 NIC4SYxHfW6ldHnvckBCe3OjeR?= MYeyOVAwOzVyIN88US=> M4G2cVQ5yqCqwrC= M{HOVYVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? NXzFPHFIOjV3NUSyNlM>
U118  NXPybHNqTnWwY4Tpc44hSXO|YYm= M2\lWVI2OC9|NUCg{txO NFnQTpQ1QMLiaNMg NUjVTGd2\W6qYX7j[ZMhXE2[LXnu[JVk\WRicD3QT2MueGGwIHTlZ5Jm[XOn NEjrO2kzPTV3NEKyNy=>
U87 M3nMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6yOVAwOzVyIN88US=> NIDFbFA1QMLiaNMg Mlu2bY5kemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJHMh[W6mIFeyM23DqGOxdILlZZRm\CC5aYToJHROYA>? NUfa[IU1OjV3NUSyNlM>
A375 NX7mZ4FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK2UVUxPDkEoHlCpC=> MXzJR|UxRTJ4NTFOwG0> MU[yOVUzPDV3Mh?=
A2058 M1zIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFToPHg1QMLiaNMg MkjOTWM2OD1zMjFOwG0> MUmyOVUzPDV3Mh?=
M238 M2TpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[0POKhcMLi NYDXflc4UUN3ME20NEDPxE1? Mnz0NlU2OjR3NUK=
M249 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7wOFjDqGkEoB?= MV3JR|UxRTJ3NDFOwG0> NYLtOpliOjV3MkS1OVI>
M21 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUO0POKhcMLi M2nYSWlEPTB;MkKxJO69VQ>? MkPONlU2OjR3NUK=
U251 MV\DfZRwfG:6aYT5JGF{e2G7 NHfxOWQzOCEQvF5CpC=> M3POfVQ5yqCqwrC= M2PBTJJm\HWlZXTzJJRp\SCyZYLj[Y51[WenczDv[kBkd2yxbnnld{Bnd3KvZXS= NWPINnBKOjV2M{SzPFE>
LN229 NFG0XXVEgXSxdH;4bZR6KEG|c3H5 NGXBbJgzOCEQvF5CpC=> M1jBSVQ5yqCqwrC= NGPSUXRz\WS3Y3Xkd{B1cGVicHXyZ4VvfGGpZYOgc4Yh[2:ub37p[ZMh\m:{bXXk NEO5XHQzPTR|NEO4NS=>
U373MG-LUC Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3qO|IhcA>? M{D6c2lEPTB-NkCwJO69VQ>? M1K5UFI2PDNzOUWz
U87  M1yycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;MXpUzPS1{MECg{txO M1\0blQ5yqCqwrC= MojmbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NEjYfY4zPTRyMEe0OS=>
U251 NIHmN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXeyOU0zODBizszN NX[3b3JXPDkEoHlCpC=> M1XwVolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFT4N4MzPTRyMEe0OS=>
U251 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjyUFVXOTByLUSwNEDPxE1? MmjNO|IwQTZiaB?= NVvvSpRVfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg NVvaRZB3OjV|N{WyO|E>
U373 M1rrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlOyNVAxNTRyMDFOwG0> NGjKVHI4Oi97NjDo MXX0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? MlnDNlU{PzV{N{G=
U343 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;FW|ExOC12MECg{txO NFLROGg4Oi97NjDo Mn20eIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi MV6yOVM4PTJ5MR?=
U87MG-luc2 NEHYVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jVZlExOC12MECg{txO MUm3Nk86PiCq MoLWeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi Mn7qNlU{PzV{N{G=
U87 NHS3VFRHfW6ldHnvckBCe3OjeR?= NYrFcGZyOjByIN88US=> M1WyRVQ5KGh? NGW4NYhqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w Ml3RNlU{Ozd5MkG=
U251 MV7GeY5kfGmxbjDBd5NigQ>? NV7NXpd7OjByIN88US=> M{TUWlQ5KGh? M2K3T4lv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? MnnCNlU{Ozd5MkG=
A172 MV7GeY5kfGmxbjDBd5NigQ>? NHrKU5YzODBizszN NHSxVoU1QCCq M2i4Nolv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? MnK5NlU{Ozd5MkG=
U251 M3XGWmZ2dmO2aX;uJGF{e2G7 MlXaNlAxKM7:TR?= M3nCZVQ5KGh? MoXDbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? MWGyOVM{Pzd{MR?=
A172 MnHZSpVv[3Srb36gRZN{[Xl? NVvHeHRkOjByIN88US=> MWq0PEBp M{nObIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBDWkODMTygRnJESTJuIGLBSFUyKGGwZDDGRW5ETDJ? M3\5bVI2OzN5N{Kx
U87 NH;SfYlHfW6ldHnvckBCe3OjeR?= NHjGTnczODBizszN NHrDe2kzPC95Mj:xNlAhcA>? MXTpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> M3LMVFI2OzN5N{Kx
U251 M1zPTGZ2dmO2aX;uJGF{e2G7 M3frWVIxOCEQvF2= MkfDNlQwPzJxMUKwJIg> M2m5VIlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MnnrNlU{Ozd5MkG=
A172 NELJclRHfW6ldHnvckBCe3OjeR?= MWiyNFAh|ryP M3jzdFI1Nzd{L{GyNEBp Mlu4bY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6 MV:yOVM{Pzd{MR?=
SNB19V M33SNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnkdFM4KGR? MYDEUXNQ MXPHTVUxRTN3LkhCtVEzKM7:TR?= NHHPXIUzPTJ5N{S0NS=>
SNB19M MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\hXVch\A>? MlfDSG1UVw>? NFS0e5lIUTVyPUS2PU46yrF6ODFOwG0> MomwNlUzPzd2NEG=
SNB19VR M{XUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7BcY1bPyCm Mn\RSG1UVw>? NWHpc2t4T0l3ME2yPFAvOsLzMUig{txO M1jrXlI2Ojd5NESx
U373V NHPl[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXK3JIQ> MWrEUXNQ NUDBZphQT0l3ME22PE4xyrF|MjFOwG0> MojzNlUzPzd2NEG=
U373M M2jSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLrR|k4KGR? NV75ZZB7TE2VTx?= MVHHTVUxRTN4OD63xtE5PiEQvF2= MmLTNlUzPzd2NEG=
U373VR NImyUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr4Rnc4KGR? MWfEUXNQ NUP3dndiT0l3ME2yPFgvQMLzM{Og{txO NULybXJOOjV{N{e0OFE>
U87MG MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HkUlch\A>? NVXVO5RpTE2VTx?= MonVS2k2OD1|OD6zxtEzOCEQvF2= MkHtNlUzPzd2NEG=
HCT116 NE\DVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF71fmY4KGR? M3vsOGROW09? Mnu3S2k2OD13N{muPeKyOzJizszN NHm4VGUzPTJ5N{S0NS=>
DLD1 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;zSWhbPyCm MnqySG1UVw>? MXXHTVUxRTVyMT60xtE6OyEQvF2= M37MXFI2Ojd5NESx
MRC5 NF7hcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq4V5o4KGR? M2fEUWROW09? NX3Bc|ZmT0l3ME20OFkvPMLzODFOwG0> M2OzUlI2Ojd5NESx
SNB19V  M2rFRmZ2dmO2aX;uJGF{e2G7 MnHzNVAxKM7:TdMgWG1b NXq5bHRkOC15MjDo MkO5bY5kemWjc3XzJO6{UDKDWDDlfJBz\XO|aX;uJIJmfHenZX6gNVYh[W6mIEeyJIg> NIPyPYczPTJ5N{S0NS=>
T98G  MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfwPIQ2PS9zMD:xOUDPxE1? NFHud3czPMLiaB?= MlTLbY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= MlrWNlUzPjJ7NkG=
U251  Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPT[5NCPS9zMD:xOUDPxE1? M33VWlI1yqCq NVzIZZU5cW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wt[IVx\W6mZX70cJkh[W[2ZYKgZ49v[2:vaYThcpQufGWvb4rvcI9ucWSnIIfpeIghVlCnNj3QSHQ> M2nmPFI2OjZ{OU[x
T98G  NYL6OFNXTnWwY4Tpc44hSXO|YYm= M1rXUFE2KM7:TR?= MX6yOOKhcA>? NW[2T3MzcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz MVqyOVI3Ojl4MR?=
U251  M3X0OWZ2dmO2aX;uJGF{e2G7 MlT1NVUh|ryP NX3l[|RMOjUEoHi= M1H6Z4lv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?= NGLOd5MzPTJ4Mkm2NS=>
U-87 MG M36wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX23NkBp NIrmTZpKSzVyPUCuPVMhdU4EoB?= NGT4OlMzPTJ2NUOzNi=>
U-118 MG M2HTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHRO|IhcA>? M{TI[GlEPTB;MT6wOUBuVcLi MlPMNlUzPDV|M{K=
U87 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvQNlQhcA>? M13IUmlEPTB;Mk[wMlM1KM7:TdMg MYCyOVE4OzJ|Mx?=
U87 GSLCs MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrFenhxOjRiaB?= NIHv[phKSzVyPUe2Ok4yOSEQvF5CpC=> NYGzcIJDOjVzN{OyN|M>
U87MG NHLRT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXO3NkBp MnXETWM2OD1zNT62NlUh|ryPwrC= NVrRT45EOjVyNUC5NVU>
U251 NYLNUVFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjRZ4cyODBvNECwJO69VQ>? NWjCfZhUPDhiaB?= NIH3cJJFVVOR NI\mNY1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVPhTFNYOjR4MkO3N|Y>
U87 NWD2PIRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO5[Gx6OTByLUSwNEDPxE1? NUmyRmRKPDhiaB?= NIPMbJVFVVOR Mn:ybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVGyOFYzOzd|Nh?=
MDA-MB-231-br NY\vd5Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jZOFAuOTBizszN M3jFR|Q5KGh? NXvRXZdNTE2VTx?= M2PCcolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUOyOFYzOzd|Nh?=
HCC-1937 MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHBNE0{ODBizszN MofxOFghcA>? Mm\ISG1UVw>? MXzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MonlNlQ3OjN5M{[=
MDA-MB-231 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvYZYIxNTRyIN88US=> NGLMVXE1QCCq MnO0SG1UVw>? M2jueYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NGT1R|gzPDZ{M{ezOi=>
MDA-MB-468 M3v0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy5N|U5OC13MECg{txO M{fXOVQ5KGh? M2P4VmROW09? M4C2c4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M122eFI1PjJ|N{O2
T47D NHfD[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PwPVAuOTByIN88US=> M1;Dc|Q5KGh? MVvEUXNQ M1;vRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmXwNlQ3OjN5M{[=
MCF7 NV[2UIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGwMVExODBizszN M3jEcVQ5KGh? MUDEUXNQ M{HaZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUKyOFYzOzd|Nh?=
Hs683 M{n6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDB[2ZwOC1zMECwJO69VQ>? MkHGPVYhcA>? NHPZbVJKSzVyPUGyPE46KM7:TR?= MVyyOFQ6PTlyNx?=
U87 NHOwbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\oZ|AuOTByMDFOwG0> MnnVPVYhcA>? NFX5Z|hKSzVyPUG4MlQ2KM7:TR?= NEHES3UzPDR7NUmwOy=>
LNZ308 M{LHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LBNFAuOTByMDFOwG0> NVWzdnJJQTZiaB?= NI[1OW1KSzVyPUOyOk44KM7:TR?= NYPhfm9nOjR2OUW5NFc>
U87 M3\y[GFxd3C2b4Ppd{BCe3OjeR?= MU[xNFAh|ryP Mlv6OFghcA>? M3zJWmROW09? NXTI[phkcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> MlnWNlQ1QDF3OE[=
U251  NE\zcYxCeG:ydH;zbZMhSXO|YYm= NEjhZ3kyODBizszN NUnzU5VOPDhiaB?= NFfwNJpFVVOR M3\SOYlv[3KnYYPld{B1cGViY3HzdIF{\S1|L{egZYN1cX[rdIm= NHHMbogzPDR6MUW4Oi=>
U251 NUDyRm5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLSeoszPCCq NYHqcW1WUUN3ME24Ok4zQeLCidMx5qCKOS53ODFOwG0> Mki0NlQ{OjZ7NUS=
U251 M2rucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX60PEBp M4S0emlEPTB;N{WuN|TjiIoEsfMAjVEvODJizszN Mkf1NlQ{OjZ7NUS=
U251 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDUO|IhcA>? NILzRXRKSzVyPUeyMlQz6oDLwsJihKkyNjR3IN88US=> M2PTdFI1OzJ4OUW0
U251 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm4T3A6PiCq NXz3U|drUUN3ME22PU45OuLCidMx5qCKOy5yNDFOwG0> NIn6XZMzPDN{Nkm1OC=>
T98G NVPxbJh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H1SlAuPzVyIN88US=> MXO3Nk86PiCq MmnXbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2LUblI1OzJ2MEiw
U251-MG M{ToUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;UW|UxNThyMDFOwG0> MWq3NkBp MWrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MoO3NlQxQTN4M{C=
D54-MG Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j5UlAuQDByIN88US=> Mn;kO|IhcA>? MVLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MmL6NlQxQTN4M{C=
SHG-44 M4exZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle1NVAuOjByIN88US=> M3juTVk3KGh? M4\YfWlEPTB;OT63N{DDuSB{LkGyJO69VQ>? NX22c5RCOjRyNkW1Olk>
U373  MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHNNVAuOjByIN88US=> NVznPFF{QTZiaB?= NXnCdpdwUUN3ME2xNE4yOyEEsTCxMlAzKM7:TR?= NXTBWIdpOjRyNkW1Olk>
HT-29  MUPGeY5kfGmxbjDBd5NigQ>? M4X1[FUxOCEQvF2= NXT3THd2OjRxNEigbC=> NITZdXBmdmijbnPld{B1cGVibHX2[Yx{KG:oIN8zMWgzSVkEoB?= NEjscVkzPDB|OEC2PC=>
PC-3  MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVywMVI2KM7:TR?= NX7pT2d3PDhiaB?= MVjpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> M4PjNlI{PzR4OUO0
PC-3  NIXZXo5CeG:ydH;zbZMhSXO|YYm= Mlu3NlUh|ryP MWC0PEBp MWDpcoR2[2W|IHHwc5B1d3OrczD3bIlkcCClYX6gZoUheG:2ZX70bYF1\WRiYomgcJlkd3CnbnW= M4rEe|I{PzR4OUO0
T98G NV3UfIhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXHenZXPTBvNECwJO69VQ>? NHmzeZYyPDRiaB?= MVXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MlXCNlM4OTV2OUm=
U87-MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvYPJIyODBiwsXN MnTYO|IhcA>? NFXxbmVqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE NFfwNGgzOzZ7Nke4PC=>
U251-MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX3NVAxKML3TR?= M4\ON|czKGh? MoTVbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>? M{jFNVI{Pjl4N{i4
LNT-229 M3;GOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEToT5U{NTFyMDFOwG0> M1X2[lI1KGh? MWHpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MX6yN|Y3PzZ|Mh?=
T98G MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LCeFExNTdyMDFOwG0> MmH5NlQhcA>? MX3pcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXyyN|Y3PzZ|Mh?=
U87  NHjWfWtHfW6ldHnvckBCe3OjeR?= MXexNFAhyrWP MVizJIg> NUHybWxU\WyndnH0[ZMhfGinIHzleoVteyCxZjDwR4hsOSCjbnSgdGNpczJ? NF\p[mMzOzZ4N{S2PS=>
HCT116 MnfoSpVv[3Srb36gRZN{[Xl? NVuxVYhzOTByINM1US=> M4jxOFMhcA>? Mn\MbY5lfWOnczD0bIUhS2itMTDQbI9{eGixconsZZRqd25? NVjmemZtOjN4Nke0Olk>
HCT3-6 NX:2eZI3TnWwY4Tpc44hSXO|YYm= M2DCN|ExOCEEtV2= MoHLN{Bp MlfNbY5lfWOnczD0bIUhS2itMTDQbI9{eGixconsZZRqd25? NHXtZXAzOzZ4N{S2PS=>
U-87  M{L0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fmPVAuPDBizszN M4LLcFEzKGR? NGG1fVBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{jGXFI{PjR3N{K5
U-87  NFPzPXFCeG:ydH;zbZMhSXO|YYm= NV;HdoRvOC12MDFOwG0> M4TOeVMwPiCm NX:yZWt7cW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MY[yN|Y1PTd{OR?=
U-87  NXrXbXpTTnWwY4Tpc44hSXO|YYm= NYP3U|RrOC12MDFOwG0> MUKzM|Yh\A>? M12yV4lv\HWlZYOgZZV1d3CqYXf5JIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NFPkT3UzOzZ2NUeyPS=>
GB-SCC010 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjWfVE2PCCm M3Tmd2lEPTB;MkK2JO69VQ>? MlPNNlM3OTJ5NUW=
GB-SCC026 M1HIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUO0JIQ> NVfBNHRrUUN3ME21N{4yKM7:TR?= NIPsTJEzOzZzMke1OS=>
GB-SCC028 MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle1OEBl MkHjTWM2OD1zNkeg{txO MUCyN|YyOjd3NR?=
U87 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLXWlY1KGR? NVWxS3pKUUN3ME20OU4zKM7:TR?= NWfV[G9zOjN4MUK3OVU>
U87 stem cell MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\xdHhqPCCm NVLz[JBVUUN3ME22Ok44KM7:TR?= Mm\YNlM3OTJ5NUW=

... Click to View More Cell Line Experimental Data

In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03687034 Not yet recruiting Glioblastoma Leaf Vertical Inc. June 1 2019 Phase 1
NCT03776071 Not yet recruiting Glioblastoma Denovo Biopharma LLC June 2019 Phase 2
NCT03776071 Not yet recruiting Glioblastoma Denovo Biopharma LLC June 2019 Phase 2
NCT03880019 Not yet recruiting Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8 National Cancer Institute (NCI) June 7 2019 Phase 2
NCT03880019 Not yet recruiting Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8 National Cancer Institute (NCI) June 7 2019 Phase 2
NCT03687034 Not yet recruiting Glioblastoma Leaf Vertical Inc. June 1 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID